The development of denosumab, a human monoclonal antibody to receptor activator of nuclear factor kappa B ligand (RANKL), represents a novel approach to the prevention of fragility fractures in osteoporosis, skeletal complications of malignancy, and bone erosions in rheumatoid arthritis
Effects of denosumab on peripheral lymphocyte subpopulations
ROSSINI, Maurizio;VIAPIANA, Ombretta;ADAMI, Silvano;IDOLAZZI, Luca;GHELLERE, FRANCESCO;TRIPI, Gaia;ORTOLANI, RICCARDO;ZANOTTI, ROBERTA;GATTI, Davide
2016-01-01
Abstract
The development of denosumab, a human monoclonal antibody to receptor activator of nuclear factor kappa B ligand (RANKL), represents a novel approach to the prevention of fragility fractures in osteoporosis, skeletal complications of malignancy, and bone erosions in rheumatoid arthritis
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Rossini et al denosumab Endocrine 2015 .pdf
non disponibili
Tipologia:
Documento in Post-print
Licenza:
Accesso ristretto
Dimensione
289.69 kB
Formato
Adobe PDF
|
289.69 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
